Precision Psychiatry Market Size Worth USD 4,437.74 Million by 2034 | CAGR: 13.6%

The precision psychiatry market size is expected to reach USD 4,437.74 Million by 2034, according to a new study by Polaris Market Research. The report “Precision Psychiatry Market Share, Size, Trends, Industry Analysis Report: By Product Type, By Sample, By Biomarker Type, By Technology, By Application, By End User, and By Region; Market Forecast, 2026–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

What Is Precision Psychiatry?

Precision psychiatry is an approach to mental healthcare that uses genetic information, biomarkers, clinical data, and individual patient characteristics to support diagnosis and treatment decisions. It targets to identify differences in how people experience psychiatric conditions and respond to medications.

Precision psychiatry is the use of genomic profiling, biomarker testing and clinical assessments to identify the needs of individual patients. These methods may be useful for the healthcare professionals to build personalized treatment strategies. They may be used for conditions such as depression, bipolar disorder, autism, Alzheimer’s disease and Parkinson’s disease.

Growing Demand for Personalized Mental Healthcare Supports Market Growth

The increasing need for personalized mental healthcare is supporting the growth of the precision psychiatry market. Traditional psychiatric treatment may require several medication adjustments before an effective option is identified. By identifying genetic variations and biomarkers associated with medication response precision psychiatry targets to improve treatment selection.

This increasing knowledge of mental health conditions – and funding for psychiatric research – is also leading to the development of tailored approaches to treatment. To identify patient groups that may respond better to specific therapies pharmaceutical companies and research institutions are exploring biomarker-based methods.

In May 2025, Alto Neuroscience reported progress across four Phase 2 clinical trials that use precision psychiatry approaches. These trends indicate a growing interest in employing measurable patient characteristics to guide psychiatric drug development.

Questions? Request a sample or make an inquiry before buying this report by clicking the link below: Precision Psychiatry Market Report

Advances in Biomarker Testing and Genomic Research Create New Opportunities

For the precision psychiatry market advances in genetic testing and biomarker research are creating new opportunities. Genetic biomarkers can help researchers study variations associated with psychiatric conditions and differences in medication response. Blood-based testing also offers a practical approach for collecting biological samples for genomic and biomarker analysis.

Research collaborations are using genetics, brain imaging and clinical data to better understand psychiatric conditions. In July 2025, NIMHANS and the University of Oslo launched the PrecInNor initiative to advance precision psychiatry through integrated research in genetics, imaging, and data science.

However, high testing costs, need for further clinical validation, data privacy concerns, and differences in access to specialized healthcare may limit wider adoption.

Precision Psychiatry Market Report Highlights

• In 2025, North America led the precision psychiatry market with 38.5% of market revenue. Strong investment in neurogenomics, diagnostic testing, and personalized mental healthcare supports the region's market position.
• Asia Pacific is projected to register the highest CAGR of 15.2% during 2026–2034. Growing mental health awareness, expanding genomic research, and healthcare investments in China and India are supporting regional growth.
• During 2026–2034 the services segment is projected to grow at a CAGR of 14.8%. Increasing demand for genomic analysis, biomarker testing, and data interpretation is helping segment growth.
• The blood-based segment accounted for 54.6% of market revenue in 2025. Ease of sample collection and its use in genomic and biomarker testing support demand.
• The sequencing segment accounted for 32.6% of market revenue in 2025. Growing use of next-generation sequencing for genetic analysis and psychiatric biomarker discovery supports the segment.
• The depression segment is projected to grow at a CAGR of 15.1% during 2026–2034. Research into personalized treatment approaches and biomarkers associated with depression is helping segment growth.

Where Is the Precision Psychiatry Market Headed?

The precision psychiatry market is expected to benefit from continued advances in genomic testing, biomarker discovery, and personalized mental healthcare. To improve patient selection and treatment outcomes pharmaceutical companies, diagnostic laboratories, and research institutions are increasingly exploring methods.

Future growth will be dependent on the availability of clinically validated biomarkers, reliable testing methods and evidence of the value of personalized treatment approaches. For broader adoption addressing testing costs, data privacy, and access to specialized diagnostic services will also be important.

What Does the Precision Psychiatry Market Report Reveal?

• What is the projected size of the precision psychiatry market by 2034?
• What are the key factors driving market growth?
• Which product type and sample segments held the largest shares in 2025?
• Which technologies are supporting precision psychiatry research?
• Which application segments are expected to grow during the forecast period?
• Which regions are leading and expanding fastest in the market?
• Who are the key companies operating in the precision psychiatry market?

Future Outlook

The future of the precision psychiatry market will be shaped by ongoing research into the biological factors associated with mental health conditions and treatment response. Greater understanding of genetic variations and biomarkers may help researchers develop more targeted therapies. It may also improve the selection of treatments for individual patients.

The collaboration between healthcare providers, diagnostic companies, pharmaceutical companies, and research institutions is expected to generate innovations. Continued clinical validation and wider access to reliable testing will be essential to translate research findings into routine psychiatric care.

Precision Psychiatry Market report based on product type, sample, biomarker type, technology, application, end user, and region:

By Product Type Outlook (Revenue, USD Million, 2021–2034)

• Products
• Services

By Sample Outlook (Revenue, USD Million, 2021–2034)

• Blood-Based
• Non-Blood-Based
  • Saliva
  • Urine
  • Cerebral Spinal Fluid (CSF)
  • Others

By Biomarker Type Outlook (Revenue, USD Million, 2021–2034)

• Genetic Biomarker
• Protein Biomarker

By Technology Outlook (Revenue, USD Million, 2021–2034)

• Sequencing
  • Next-Generation Sequencing (NGS)
  • Sanger Sequencing
• Polymerase Chain Reaction (PCR)
  • Real-Time Polymerase Chain Reaction (RT-PCR)
  • Digital Polymerase Chain Reaction (dPCR)
• Microarray
• Immunoassay
• Liquid Chromatography-Mass Spectrometry (LC-MS)
• Others

By Application Outlook (Revenue, USD Million, 2021–2034)

• Alzheimer’s Disease
• Parkinson’s Disease
• Autism
• Depression
• Bipolar Disease
• Others

By End User Outlook (Revenue, USD Million, 2021–2034)

• Hospitals and Diagnostic Laboratories
• Academic and Research Institutions
• Others

By Regional Outlook (Revenue, USD Million, 2021–2034)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
• Latin America
  • Mexico
  • Brazil
  • Argentina
• Rest of Latin America